Drug Profile
Somatropin - Alteogen/CJ HealthCare Corporation
Alternative Names: ALT P1; CJ-40002; hGH-NexP; Recombinant human growth hormone - Alteogen/CJ HealthcareLatest Information Update: 06 Oct 2022
Price :
$50
*
At a glance
- Originator Alteogen; CJ Corporation
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Somatotropin deficiency
Most Recent Events
- 04 Oct 2022 Somatropin - Alteogen/CJ HealthCare Corporation is available for licensing as of 04 Oct 2022. http://www.alteogen.com/en/ (Alteogen website, October 2022)
- 04 Oct 2022 Alteogen plans a phase II trial for Somatotropin deficiency worldwide (SC) (Alteogen pipeline, October 2022)
- 25 Jul 2022 Phase-II development for Somatotropin deficiency is ongoing in South Korea (Alteogen pipeline, July 2022)